{"id":9051,"date":"2021-04-12T13:39:02","date_gmt":"2021-04-12T13:39:02","guid":{"rendered":"https:\/\/www.kolabtree.com\/blog\/?p=9051"},"modified":"2021-04-13T10:38:51","modified_gmt":"2021-04-13T10:38:51","slug":"top-15-covid-19-vaccine-startups-worldwide","status":"publish","type":"post","link":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/","title":{"rendered":"Top 15 COVID-19 vaccine startups worldwide"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_45_1 counter-flat ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" area-label=\"ez-toc-toggle-icon-1\"><label for=\"item-69f68fd1e9349\" aria-label=\"Table of Content\"><span style=\"display: flex;align-items: center;width: 35px;height: 30px;justify-content: center;direction:ltr;\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/label><input  type=\"checkbox\" id=\"item-69f68fd1e9349\"><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#Top_15_COVID-19_vaccine_startups_in_the_world\" title=\"Top 15 COVID-19 vaccine startups in the world\">Top 15 COVID-19 vaccine startups in the world<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#1_Aivita_Biomedical\" title=\"1. Aivita Biomedical\">1. Aivita Biomedical<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#2_Baseimmune\" title=\"2. Baseimmune\">2. Baseimmune<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#3_BioNTech\" title=\"3. BioNTech\">3. BioNTech<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#4_Centivax\" title=\"4. Centivax\">4. Centivax<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#5_Codagenix\" title=\"5. Codagenix\">5. Codagenix<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#6_Emergex_Vaccines\" title=\"6. Emergex Vaccines\">6. Emergex Vaccines<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#7_eTheRNA_immunotherapies\" title=\"7. eTheRNA immunotherapies\">7. eTheRNA immunotherapies<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#8_HDT_Bio\" title=\"8. HDT Bio\">8. HDT Bio<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#9_Meissa_Vaccines\" title=\"9. Meissa Vaccines\">9. Meissa Vaccines<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#10_Oravax_Medical\" title=\"10. Oravax Medical\">10. Oravax Medical<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#11_Osivax\" title=\"11. Osivax\">11. Osivax<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#12_Providence_Therapeutics\" title=\"12. Providence Therapeutics\">12. Providence Therapeutics<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#13_Themis\" title=\"13. Themis\">13. Themis<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#14_Vaccitech\" title=\"14. Vaccitech\">14. Vaccitech<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#15_Wingcopter_and_Zipline\" title=\"15. Wingcopter and Zipline\">15. Wingcopter and Zipline<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#About_the_Author\" title=\"About the Author\">About the Author<\/a><\/li><\/ul><\/nav><\/div>\n<p><span style=\"font-weight: 400;\"><em><a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/ahmed-elewa\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Covid-19-vaccine-startups\">Ahmed Elewa<\/a>, freelance scientist on Kolabtree, provide a rundown of the top 15 startups worldwide working on the COVID-19 vaccine.\u00a0<\/em><\/span><\/p>\n<p>When the National Institutes of Health<a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options\"> <span style=\"font-weight: 400;\">met with pharma<\/span><\/a><span style=\"font-weight: 400;\"> companies to accelerate COVID-19 vaccine development, all the big names where there; and they delivered. Now, multiple vaccines have completed clinical trials and are being administered worldwide. Most notable are vaccines from Pfizer (two shots, 95% effective), Moderna (two shots, 95% effective), Novavax (two shots \u2013 89% effective), Johnson and Johnson (single-shot 57-72% effective) and AstraZeneca (two shots \u2013 62% effective). However, despite several vaccines being available, the story isn\u2019t over yet and several challenges remain. For example, Pfizer\u2019s vaccine needs to be kept at -80 \u00b0C for long-term storage, and Moderna\u2019s at -20 \u00b0C. The need for a \u2018cold chain\u2019 to allow for vaccine distribution is a logistical hurdle that complicates vaccination. And what if the virus mutates to variants that are not recognized by current vaccines? And how can we ensure that everyone has access to vaccination?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Startups have risen to meet these challenges and are designing vaccines that do not rely on cold storage, are effective against future variants and can reach people throughout the world, not just in wealthy countries. Here are 15 startups (in alphabetical order) that are at the forefront of the race to vaccinate the world against COVID-19.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Top_15_COVID-19_vaccine_startups_in_the_world\"><\/span>Top 15 COVID-19 vaccine startups in the world<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h2><span class=\"ez-toc-section\" id=\"1_Aivita_Biomedical\"><\/span><b>1. Aivita Biomedical<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"http:\/\/aivitabiomedical.com\/\"><span style=\"font-weight: 400;\">Aivita Biomedical<\/span><\/a><span style=\"font-weight: 400;\"> is developing a COVID-19 vaccine with a personal twist. The vaccine (AV-COVID-19) is a patient-specific dendritic cell vaccine. This means that a blood sample is first extracted from a patient and the blood is enriched for monocytes, a type of white blood cell that plays a role in innate immune response. The monocytes are differentiated into dendritic cells, an immune messenger cell. Next, SARS-CoV-2 antigens are loaded onto the dendritic cells and after incubation, the vaccine is administered to the same patient who gave that blood sample. This means that the vaccine is personalized and, perhaps as important, the process can be done in minimally-equipped laboratory settings. If successful, this offers a potential for rapid scalability and mass distribution.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2016<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Patient-specific<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $56.2M (Series B $52.5M, Series A $2M <a href=\"https:\/\/www.kolabtree.com\/blog\/ensuring-reproducibility-in-ai-driven-research-how-freelance-experts-can-help-in-biotech-and-healthcare\/\">Research<\/a> Grant $1.7M)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: California Technology Ventures, Hoag Memorial Hospital, Sue &amp;. Bill Gross Stem Cell Research Center<\/span><\/li>\n<li>Stage of Development: Phase 2 (Indonesia)<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"2_Baseimmune\"><\/span><b>2. Baseimmune<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.baseimmune.co.uk\/\"><span style=\"font-weight: 400;\">Baseimmune<\/span><\/a><span style=\"font-weight: 400;\"> is a biotech startup that uses machine learning to turn big data in genomics, proteomics, and clinical data into information that can be incorporated into vaccine design. As a discovery phase biotech, Baseimmune offers their antigen discovery services and develops broad-spectrum vaccines against highly variable pathogens. The startup has five antigens in various stages of development. Earlier this year, the startup<\/span><a href=\"https:\/\/www.baseimmune.co.uk\/press-release-april-2021.html\"> <span style=\"font-weight: 400;\">closed a \u00a3685,000 investment<\/span><\/a><span style=\"font-weight: 400;\">, led by European University VC fund and Creator Fund. Their plan now is to hire a few more staff and find a big biotech partner to work with on a COVID-19 vaccine.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2019<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Computational<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Machine learning and big-data<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: \u00a3685,000 (European university VC fund and Creator Fund)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Vaccitech<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Early development<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"3_BioNTech\"><\/span><b>3. BioNTech<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">If you\u2019ve heard about COVID-19 vaccines, then you\u2019ve probably heard of<\/span><a href=\"https:\/\/biontech.de\/\"> <span style=\"font-weight: 400;\">BioNTech<\/span><\/a><span style=\"font-weight: 400;\">. This German company went from startup to superstar last year when its vaccine, developed in collaboration with Pfizer passed all clinical trials. The company went public in October 2019 and is currently worth over $27B. Like many mRNA vaccine companies, BioNTech was initially focused on cancer therapy, which benefits from personalized immunotherapy. However, the pandemic led the company to shift their focus to meeting the global need for a COVID-19 vaccine. BioNTech\u2019s technical expertise combined with Pfizer\u2019s infrastructure for large scale vaccine production produced one of the first vaccines to pass clinical trials and become administered worldwide. Though no longer a startup, BioNTech is mentioned here because it is a truly inspiring story of how a small company was able to attract significant investments (over $1B) and eventually produce a solution that saves lives.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2008<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: mRNA<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: mRNA vaccine technology<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $1.5B (Current market capitalization $27.5B)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Pfizer<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Complete<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"4_Centivax\"><\/span><b>4. Centivax<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">If you\u2019ve watched \u201c<\/span><a href=\"https:\/\/www.youtube.com\/watch?v=1nmmWePN1jE\"><span style=\"font-weight: 400;\">Pandemic<\/span><\/a><span style=\"font-weight: 400;\">\u201d on Netflix, then you know Jacob Glanville and his ambitious vision to create one vaccine to treat all future versions of flu. The documentary follows Jacob and his assistant Sarah Ives as they travel to their animal facility in Guatemala to conduct an important preclinical test for their vaccines. A major strength of this startup is their combination of computational immunology, bioengineering, and robotics, which has allowed them to develop a pipeline of molecules with unprecedented biophysical properties. Glansville recently<\/span><a href=\"https:\/\/patents.google.com\/patent\/US20210070808A1\/en\"> <span style=\"font-weight: 400;\">patented<\/span><\/a><span style=\"font-weight: 400;\"> an epitope focusing technology, Centivax, which aids in designing universal vaccines against rapidly mutating pathogens such as influenza, HIV, and the flaviviruses. Wait, but the startup in the documentary was called \u2018Distributed Bio\u2019. Well, that was until they were<\/span><a href=\"https:\/\/www.criver.com\/insights\/charles-river-acquires-distributed-bio\"> <span style=\"font-weight: 400;\">acquired<\/span><\/a><span style=\"font-weight: 400;\"> by Charles River Laboratories International for $83,000,000. After the acquisition, Jacob Glanville transitioned to function as CEO of the spinout Centivax, which focuses on universal vaccines, therapeutic antibodies against COVID-19, and other infectious diseases. To manufacture their vaccine, Centivax has<\/span><a href=\"https:\/\/www.biospace.com\/article\/revolutionizing-the-manufacturing-process-for-faster-vaccine-and-therapeutic-production\/\"> <span style=\"font-weight: 400;\">partnered<\/span><\/a><span style=\"font-weight: 400;\"> with<\/span><a href=\"https:\/\/www.swiftcovid.com\/\"> <span style=\"font-weight: 400;\">SwiftScale Biologics<\/span><\/a><span style=\"font-weight: 400;\"> to leverage their platform that uses their cell-free manufacturing of glycosylated proteins. So far, work is on a COVID-19 vaccine is preclinical, but we hope a clinical trial for a universal vaccine against coronaviruses is in sight.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2010<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Universal Vaccine<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: Acquisition December, 2020 by Charles River Laboratories International ($83M)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: SwiftScale Biologics<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"5_Codagenix\"><\/span><b>5. Codagenix<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/codagenix.com\/\"><span style=\"font-weight: 400;\">Codagenix<\/span><\/a><span style=\"font-weight: 400;\"> uses a breakthrough platform technology called SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets. The company has been developing a COVID-19 vaccine as well. They will be targeting the spike protein, along with all other structural and non-structural proteins of SARS-CoV-2. Codagenix is working on bringing the vaccine into Phase 1 trials this year. After that, through a partnership with the<\/span><a href=\"https:\/\/www.seruminstitute.com\/\"> <span style=\"font-weight: 400;\">Serum Institute<\/span><\/a><span style=\"font-weight: 400;\">, they will manufacture and distribute the vaccine under a US Emergency Use Authorization (EUA).<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2011<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Synthetic Attenuated Virus Engineering<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $20M (Series B: Adjuvant Capital, Topspin Partners and Euclidean Capital)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Serum Institute<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development:<\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04619628\"> <span style=\"font-weight: 400;\">Phase 1 Clinical study<\/span><\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"6_Emergex_Vaccines\"><\/span><b>6. Emergex Vaccines<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/emergexvaccines.com\/\"><span style=\"font-weight: 400;\">Emergex Vaccines<\/span><\/a><span style=\"font-weight: 400;\"> offers affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. The Company\u2019s<\/span><\/p>\n<p><span style=\"font-weight: 400;\">underlying platform technology enables rapid development of vaccines to entire families of pathogens, compared to traditional approaches that can take years to develop and scale vaccines for single pathogens. Moreover, their set-point vaccines modify the initial immune status of recipients in a way that primes their immune systems to recognize subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease. Since their vaccines are synthetic with no biological components, Emergex claims that its vaccines are much safer as they carry no infection risk from live attenuated pathogens, are much cheaper to produce since they do not require culturing, and can be conveniently transported and administered even in remote parts of the world. Last January, Emergex<\/span><a href=\"https:\/\/emergexvaccines.com\/emergex-vaccines-signs-collaboration-agreement-with-brazils-bio-manguinhos-fiocruz-for-the-development-of-a-covid-19-vaccine\/\"> <span style=\"font-weight: 400;\">announced<\/span><\/a><span style=\"font-weight: 400;\"> that it signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex\u2019s next generation synthetic T-Cell vaccine technology.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2016<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Synthetic T-Cell vaccine technology<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $12.3M (Vickers Venture Partners, Innovate UK and Trend Investment Group)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Bio-Manguinhos and Fiocruz<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"7_eTheRNA_immunotherapies\"><\/span><b>7. eTheRNA immunotherapies<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.etherna.be\/\"><span style=\"font-weight: 400;\">eTheRNA<\/span><\/a><span style=\"font-weight: 400;\"> was established in January 2013 as a spin-off company from the \u2018Vrije Universiteit Brussel\u2019 (VUB), following the development of its TriMix mRNA technology, which boosts dendritic cells leading to more effective immunization. A year ago, it was<\/span><a href=\"https:\/\/www.prnewswire.com\/news-releases\/etherna-launches-an-international-consortium-and-starts-development-of-cross-strain-protective-cov-2-mrna-vaccine-for-high-risk-populations-301028630.html\"> <span style=\"font-weight: 400;\">announced<\/span><\/a><span style=\"font-weight: 400;\"> that eTheRNA formed a consortium with North American and European partners to access tools to develop a novel mRNA COVID-19 vaccine. No further related press releases have been issued. Administered intranasally, the proposed vaccine is intended primarily for high-risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-19 genome. eTheRNA and its partners have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrollment planned for 2021.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2013<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: mRNA, Intranasal<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: TriMix technology<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $73M (Series B \u20ac34M, Series A \u20ac24M, Research Grants \u20ac7.9M)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: EpiVax, Nexelis, Reprocell and Vaxinfectio<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"8_HDT_Bio\"><\/span><b>8. HDT Bio<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">What makes<\/span><a href=\"https:\/\/www.hdt.bio\/\"> <span style=\"font-weight: 400;\">HDT Bio<\/span><\/a><span style=\"font-weight: 400;\"> special is their innovative LION platform. LION is an acronym for Lipid InOrganic Nanoparticles, which stimulate the immune system for a better response to vaccines. That is why the vaccine under development by HDT Bio is a potential alternative for \u201cnon-responders\u201d, people who do not develop immunity after vaccination. Working together with PAI Life Sciences and scientists at the University of Washington, the COVID-19 vaccine HDT Bio is developing (HDT-301) promises to rapidly generate a broad immune response against coronavirus with just one injection. Recently, HDT Bio and its collaborators received a $8.2M grant from the NIH in support of preclinical and clinical activities to accelerate development of HDT-301 and the company is currently applying for permission to start human clinical trials in the US. However, HDT Bio faces the challenge that according to FDA regulations, LION particles are considered a drug separate from the vaccine. This will complicate securing approvals to begin clinical trials. Luckily, regulators in Brazil, China, South Africa, and India, where HDT Bio is hoping to launch its product, do not consider LIONs as a separate drug since it isn\u2019t the active component. This means that we might be seeing clinical trials for HDT-301 in other countries before starting in the US.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2017<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: mRNA<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Lipid inorganic nanoparticles &#8211; LIONs<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $14.3M ($6M Zoic Capital and Eric Anschutz, $8.3M NIH-NIAID)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Several, including NIH\/NCI, CDC, PAI Life Sciences, University of Washington and Gennova Biopharmaceuticals.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"9_Meissa_Vaccines\"><\/span><b>9. Meissa Vaccines<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.meissavaccines.com\/\"><span style=\"font-weight: 400;\">Meissa Vaccines<\/span><\/a><span style=\"font-weight: 400;\"> applies synthetic biology and genetic engineering to respiratory viruses for the rational design of vaccine strains that solve challenging obstacles in modern vaccinology such as suboptimal immune responses, vaccine stability, and manufacturing. The company uses their proprietary AttenuBlock&#x2122; synthetic biology and codon deoptimization platform and their vaccines are formulated to be delivered as a single, intranasal, adjuvant-free, needle-free dose and are designed to prevent infection and disease and generate a strong, durable immune response. In March, 2021 Meissa announced that it received clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical study of MV-014-212, the company\u2019s intranasal live attenuated chimeric COVID-19 vaccine candidate.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2014<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant, Single Dose, Intranasal Drops<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: AttenuBlock&#x2122; and codon deoptimization<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $33.4M (Morningside Venture Investments)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Emory University and Children\u2019s Healthcare of Atlanta<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development:<\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04798001\"> <span style=\"font-weight: 400;\">Phase 1 Clinical study<\/span><\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"10_Oravax_Medical\"><\/span><b>10. Oravax Medical<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.ora-vax.com\/\"><span style=\"font-weight: 400;\">Oravax<\/span><\/a><span style=\"font-weight: 400;\"> is the product of a collaboration between Premas Biotech and Oramed. Premas Biotech specializes in developing recombinant proteins for vaccine development. Such proteins are often \u201cdifficult to express proteins\u201d (DTE-Ps) but Premas\u2019 innovative D-Crypt platform is optimized for high-yield production of DTE-Ps, singularly, or in combination. On the other hand, Oramed is specialized in oral drug delivery, so you can see where Oravax is headed; an oral COVID-19 vaccine. Oravax is built on exclusive licenses from both companies, which has persuaded other unnamed stakeholders to come on board. The candidate vaccine under development is designed to confer immunity against spike, membrane and envelope targets and is therefore potentially less vulnerable to viral escape as it has three targets. What\u2019s really exciting about Oravax\u2019s plan is that the vaccine will be oral. This means that you can receive your vaccine in the mail without cold storage and without the need for a qualified person to administer a shot.<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2021<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant, Oral<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: POD&#x2122; (Protein Oral Delivery)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: Unknown<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Oramed Pharmaceuticals Inc. and Premas Biotech Pvt. Ltd.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"11_Osivax\"><\/span><b>11. Osivax<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"http:\/\/www.osivax.com\/\"><span style=\"font-weight: 400;\">Osivax<\/span><\/a><span style=\"font-weight: 400;\"> is a French company developing a universal flu vaccine for both current and future influenza infections. One of the promising vaccine candidates, OVX836, is currently in Phase 2a clinical development. A feature of Osivax\u2019s approach is to target the virus nucleocapsid instead of the spike protein targeted by most vaccines. Unlike the spike protein which mutates often leading to new variants, the nucleocapsid is less prone to mutation. Additionally, the nucleoprotein of flu viruses is very similar to coronaviruses, which has allowed Osivax to leverage its platform to develop a universal vaccine against all existing and emerging coronavirus infections (including COVID-19). As a company, Osivax is focused on providing proof-of-concept studies using its oligoDOM\u00ae technology, which relies on more than 12 years of R&amp;D and is protected by two patent families.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2017<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Versatile (i.e., can be applied to recombinant or mRNA vaccines)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: oligoDOM\u00ae technology platform<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: \u20ac40.8M (Series B \u20ac15M, Series A \u20ac8M, Seed \u20ac2.7M, Research Grants \u20ac15.1M)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Numerous, see company<\/span><a href=\"http:\/\/www.osivax.com\/partners.html\"> <span style=\"font-weight: 400;\">webpage<\/span><\/a><span style=\"font-weight: 400;\"> for full listing.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Preclinical<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"12_Providence_Therapeutics\"><\/span><b>12. Providence Therapeutics<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Brad Sorenson started<\/span><a href=\"https:\/\/www.providencetherapeutics.com\/\"> <span style=\"font-weight: 400;\">Providence Therapeutics<\/span><\/a><span style=\"font-weight: 400;\"> when his son was diagnosed with Stage 4 brain cancer the day after his 13<\/span><span style=\"font-weight: 400;\">th<\/span><span style=\"font-weight: 400;\"> birthday. He was given less than a year to live but is still with us today, 7 years later. The feeling of helplessness that comes with being diagnosed with cancer motivated Sorenson to start working on developing cancer mRNA vaccines that can be tailored and individualized for each patient. Although 2020 was supposed to be the year this Canadian company would begin clinical trials, they put the program on hold and focused on applying their expertise to develop a vaccine for COVID-19. The feeling of helplessness that comes with lockdowns and not being able to be with family is reminiscent to the feeling that Providence Therapeutics was established in order to overcome. In Sorenson\u2019s words, they had a moral obligation to do something with the cutting-edge technology they had developed. In 4 weeks, the company had designed a vaccine, and then proceeded to secure licenses, establish collaborations with research centers, complete preclinical trials and manufacture enough vaccine in Canada to complete clinical trials and was given the green light to proceed. All this was accomplished without government support and despite COVID-19 restrictions that restrict the number of employees at work.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Providence Therapeutics is Canada&#8217;s only mRNA vaccine company and while their platform does not include major innovations, the infrastructure and expertise they have makes them well positioned to help Canada meet their national vaccine needs and the needs of other countries that may be underserved by large pharma programs. In October 2020, Providence Therapeutics confirmed that the Government of Canada will be supporting Phase 1 clinical trials of its promising and proprietary mRNA COVID-19 vaccine, PTX-COVID19-B. The company envisions moving into Phase 2 in May 2021, pending regulatory approval. Looking forward, Providence Therapeutics has already reached an agreement with the Government of Manitoba (a Canadian province) to supply 2 million doses of the vaccine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Unlike big pharma companies, Providence Therapeutics is a startup with relatively limited resources. However, it\u2019s key strength seems to be its ability to generate enough trust and support to get the right partners on board. In order to be able to manufacture their PTX-COVID19-B vaccine at sufficient scale, the company has secured partnerships with several companies and entities, the leading ten are:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Genevant \u2013 Lipid IP &amp; supply \u2013 British Columbia<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Northern RNA Inc. \u2013 Raw materials &amp; finished mRNA drug substance \u2013 Alberta<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Emergent BioSolutions Canada Inc. \u2013 Formulation &amp; fill finish \u2013 Manitoba<\/span><\/li>\n<li><span style=\"font-weight: 400;\">University of Toronto \u2013 Preclinical testing of vaccine &amp; future variants \u2013 Ontario<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Ontario Institute of Cancer Research \u2013 Sequencing of vaccine product \u2013 Ontario<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Sunnybrook Research Institute \u2013 Laboratory for process development and scale up \u2013 Ontario<\/span><\/li>\n<li><span style=\"font-weight: 400;\">LMC Manna Research \u2013 Clinical trial sites \u2013 Multiple Provinces<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Charles River Laboratories \u2013 Preclinical testing of vaccine &amp; future variants \u2013 Quebec<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Intrinsik Corporation \u2013 Regulatory consulting \u2013 Ontario<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Cirion BioPharma Recherche \u2013 Clinical laboratory testing \u2013 Quebec<\/span><\/li>\n<\/ul>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2015<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: mRNA<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: <\/span><i><span style=\"font-weight: 400;\">An entrepreneurial catalyst to provide a \u2018Made in Canada\u2019 vaccine.<\/span><\/i><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: ~$10M (Venture Round $3.5M, $4.7M Government of Canada, ~$2M Next Generation Manufacturing Canada)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Numerous (see above)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development:<\/span><a href=\"https:\/\/www.providencetherapeutics.com\/providence-therapeutics-announces-first-subject-has-been-dosed-in-covid-19-vaccine-trial\">\u00a0<span style=\"font-weight: 400;\">Phase 1 Clinical study<\/span><\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"13_Themis\"><\/span><b>13. Themis<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Themis Bioscience was an Austrian start-up biotechnology company developing vaccines to prevent infectious diseases. In May 2020, Merk<\/span><a href=\"https:\/\/www.merck.com\/stories\/merck-announces-three-significant-scientific-efforts-in-the-fight-against-covid-19\/\"> <span style=\"font-weight: 400;\">announced<\/span><\/a><span style=\"font-weight: 400;\"> it was acquiring Themis to develop a COVID-19 vaccine (V591). The acquisition was completed in June and by August, the first patient was dosed in the Phase 1 clinical study of V591. However, in January 2021, Merck announced that it was discontinuing work on the V591 vaccine program altogether. Some<\/span><a href=\"https:\/\/www.drugdeliverybusiness.com\/merck-eyes-tiny-patches-as-a-vaccine-delivery-method\/\"> <span style=\"font-weight: 400;\">speculate<\/span><\/a><span style=\"font-weight: 400;\"> that Merck indented to combine Themis\u2019 vaccine with an innovative method for delivery that would circumvent the need for cold storage. Despite not reaching the market with its COVID-19 vaccine development, Themis represents a strong start-up that consistently succeeded in attracting investments before being acquired by a leading pharmaceutical company.\u00a0<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2009<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Unknown<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $81.6M (before Merck acquisition for an undisclosed amount)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Merck<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Discontinued (January 2021)<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"14_Vaccitech\"><\/span><b>14. Vaccitech<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Co-founded by Adrian Hill, director of the Jenner Institute, this Oxford startup is behind AstraZeneca\u2019s COVID-19 vaccine. The<\/span><a href=\"https:\/\/www.jenner.ac.uk\/\"> <span style=\"font-weight: 400;\">Jenner Institute<\/span><\/a><span style=\"font-weight: 400;\"> is one of the oldest and most renowned vaccine research centers in the world and company is built on some of the institutes ground breaking innovations in vaccine development.<\/span><a href=\"https:\/\/www.vaccitech.co.uk\/\"> <span style=\"font-weight: 400;\">Vaccitech<\/span><\/a><span style=\"font-weight: 400;\">\u2019s proprietary chimpanzee adenovirus technology is an excellent way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The latest Series B investments secured $168M in funding and was led by M&amp;G Investment Management alongside participation from Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital. Importantly, numerous reports have hinted that the company is preparing to go public this year.<\/span><\/p>\n<p><b>HIGHLIGHTS:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Founded: 2016<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Kind of vaccine: Recombinant<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Innovation: Proprietary adenovirus vector vaccine technology<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Funding received: $215.6M (Series B $168M M&amp;G Investments, Series A \u00a326M GV and Sequoia Capital, Seed Round \u00a310M Oxford Sciences Innovation)<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Collaborations: Jenner Institute and AstraZeneca<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Stage of Development: Complete<\/span><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"15_Wingcopter_and_Zipline\"><\/span><b>15. Wingcopter and Zipline<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Finally, while vaccine development is a critical part of overcoming COVID-19, vaccine distribution remains a challenge. We\u2019ve seen some startups trying to overcome the delivery challenge in different ways. For example, Oravax is working an oral vaccine that wouldn\u2019t need cold storage. We\u2019ve also seen Aivita developing a vaccine development pipeline that can be executed at minimally-equipped laboratory settings. US<\/span><a href=\"https:\/\/flyzipline.com\/\"> <span style=\"font-weight: 400;\">Zipline<\/span><\/a><span style=\"font-weight: 400;\"> and German<\/span><a href=\"https:\/\/wingcopter.com\/\"> <span style=\"font-weight: 400;\">Wingcopter<\/span><\/a><span style=\"font-weight: 400;\"> are two different startups that have another creative solution to vaccine distribution, drones!<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_the_Author\"><\/span><b>About the Author<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Ahmed Elewa, PhD, is a freelancing scientist. He has a PhD in biomedical sciences from the University of Massachusetts Medical School where he researched <\/span><i><span style=\"font-weight: 400;\">C. elegans<\/span><\/i><span style=\"font-weight: 400;\"> development. As a postdoc, he studied salamander regeneration and co-founded Colorna, a Swedish startup developing rapid diagnostic tools for global health and personalized medicine. Follow him on Twitter <a href=\"http:\/\/twitter.com\/egypsci\">@egypsci<\/a> and read about his journey to freelancing in our <a href=\"https:\/\/www.kolabtree.com\/blog\/ahmed-elewa-scientific-freelancer-and-covid-19-startup-founder\/\">Featured Freelancer Spotlight<\/a>.\u00a0<\/span><\/p>\n<p>Enjoyed reading this article on COVID-19 vaccine startups? Read more interesting articles:<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"pPI7rXI6HF\"><p><a href=\"https:\/\/www.kolabtree.com\/blog\/covid-19-coronavirus-research-and-vaccine-development\/\">COVID-19: Ongoing Coronavirus Research and Vaccine Development<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;COVID-19: Ongoing Coronavirus Research and Vaccine Development&#8221; &#8212; The Kolabtree Blog\" src=\"https:\/\/www.kolabtree.com\/blog\/covid-19-coronavirus-research-and-vaccine-development\/embed\/#?secret=pPI7rXI6HF\" data-secret=\"pPI7rXI6HF\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"c95XDE7r3i\"><p><a href=\"https:\/\/www.kolabtree.com\/blog\/11-medical-devices-and-technology-innovations-that-are-transforming-health-care\/\">11 Medical Device and Technology Innovations That Are Transforming Healthcare<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;11 Medical Device and Technology Innovations That Are Transforming Healthcare&#8221; &#8212; The Kolabtree Blog\" src=\"https:\/\/www.kolabtree.com\/blog\/11-medical-devices-and-technology-innovations-that-are-transforming-health-care\/embed\/#?secret=c95XDE7r3i\" data-secret=\"c95XDE7r3i\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ahmed Elewa, freelance scientist on Kolabtree, provide a rundown of the top 15 startups worldwide working on the COVID-19 vaccine.\u00a0 When the National Institutes of Health met with pharma companies to accelerate COVID-19 vaccine development, all the big names where there; and they delivered. Now, multiple vaccines have completed clinical trials and are being administered<\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/\" title=\"Read More\">Read More<\/a><\/div>\n","protected":false},"author":12,"featured_media":9054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[442,558],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.1 (Yoast SEO v20.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Top 15 COVID-19 vaccine startups worldwide - The Kolabtree Blog<\/title>\n<meta name=\"description\" content=\"From Aivita Biomedical to Centivax, some of the most interesting startups worldwide manufacturing or delivering the COVID-19 vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top 15 COVID-19 vaccine startups worldwide\" \/>\n<meta property=\"og:description\" content=\"From Aivita Biomedical to Centivax, some of the most interesting startups worldwide manufacturing or delivering the COVID-19 vaccine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/\" \/>\n<meta property=\"og:site_name\" content=\"The Kolabtree Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kolabtree\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-12T13:39:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-13T10:38:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2021\/04\/Covid-19-vaccine-startups.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ramya Sriram\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:site\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ramya Sriram\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Top 15 COVID-19 vaccine startups worldwide - The Kolabtree Blog","description":"From Aivita Biomedical to Centivax, some of the most interesting startups worldwide manufacturing or delivering the COVID-19 vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/","og_locale":"en_US","og_type":"article","og_title":"Top 15 COVID-19 vaccine startups worldwide","og_description":"From Aivita Biomedical to Centivax, some of the most interesting startups worldwide manufacturing or delivering the COVID-19 vaccine.","og_url":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/","og_site_name":"The Kolabtree Blog","article_publisher":"https:\/\/www.facebook.com\/kolabtree","article_published_time":"2021-04-12T13:39:02+00:00","article_modified_time":"2021-04-13T10:38:51+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2021\/04\/Covid-19-vaccine-startups.jpg","type":"image\/jpeg"}],"author":"Ramya Sriram","twitter_card":"summary_large_image","twitter_creator":"@kolabtree","twitter_site":"@kolabtree","twitter_misc":{"Written by":"Ramya Sriram","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#article","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/"},"author":{"name":"Ramya Sriram","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/81992f5863a1b06d132a47822e7b4400"},"headline":"Top 15 COVID-19 vaccine startups worldwide","datePublished":"2021-04-12T13:39:02+00:00","dateModified":"2021-04-13T10:38:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/"},"wordCount":3204,"commentCount":0,"publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"articleSection":["Biotechnology","COVID-19 resources"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/","url":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/","name":"Top 15 COVID-19 vaccine startups worldwide - The Kolabtree Blog","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/#website"},"datePublished":"2021-04-12T13:39:02+00:00","dateModified":"2021-04-13T10:38:51+00:00","description":"From Aivita Biomedical to Centivax, some of the most interesting startups worldwide manufacturing or delivering the COVID-19 vaccine.","breadcrumb":{"@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kolabtree.com\/blog\/top-15-covid-19-vaccine-startups-worldwide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kolabtree.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Top 15 COVID-19 vaccine startups worldwide"}]},{"@type":"WebSite","@id":"https:\/\/www.kolabtree.com\/blog\/#website","url":"https:\/\/www.kolabtree.com\/blog\/","name":"The Kolabtree Blog","description":"Expert Views on Science, Innovation and Product Development","publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kolabtree.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kolabtree.com\/blog\/#organization","name":"Kolabtree","url":"https:\/\/www.kolabtree.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Kolabtree"},"image":{"@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kolabtree","https:\/\/twitter.com\/kolabtree","https:\/\/instagram.com\/kolabtree","https:\/\/www.linkedin.com\/company\/kolabtree","https:\/\/en.m.wikipedia.org\/wiki\/Kolabtree"]},{"@type":"Person","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/81992f5863a1b06d132a47822e7b4400","name":"Ramya Sriram","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8100b45c960ebbbbe420e8b3f250515f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8100b45c960ebbbbe420e8b3f250515f?s=96&d=mm&r=g","caption":"Ramya Sriram"},"description":"Ramya Sriram manages digital content and communications at Kolabtree (kolabtree.com), the world's largest freelancing platform for scientists. She has over a decade of experience in publishing, advertising and digital content creation.","url":"https:\/\/www.kolabtree.com\/blog\/author\/ramyas\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9051"}],"collection":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/comments?post=9051"}],"version-history":[{"count":7,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9051\/revisions"}],"predecessor-version":[{"id":9065,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9051\/revisions\/9065"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media\/9054"}],"wp:attachment":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media?parent=9051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/categories?post=9051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/tags?post=9051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}